Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

LB PHARMACEUTICALS INC (LBRX)

$35.01 +1.13% NASDAQ: LBRX · 15-min delayed
  • NEW YORK, New York
  • Public · NASDAQ: LBRX
  • 27 employees
$818.1MMarket cap
-$25.2MNet income
27Employees
LBRXNASDAQ
2025IPO

About LB PHARMACEUTICALS INC

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$25.2M
Total assets
$312.9M
Market cap
$818.1M

Source: SEC EDGAR · updated Jun 7, 2026

FY 2025

Financial statements

Income statement

Operating expenses
$30.4M
Income tax
$1.0K
Net income
-$25.2M
EPS (basic)
$-3.13
EPS (diluted)
$-3.13

Balance sheet

Total assets
$312.9M
Current assets
$308.4M
Total liabilities
$11.6M
Current liabilities
$7.4M
Shareholders’ equity
$301.3M

Cash flow

Operating cash flow
-$35.2M
Investing cash flow
-$39.9M
Financing cash flow
$302.6M
Net cash flow
$227.5M

Statements via Polygon.io (SEC filings)

NASDAQ: LBRX
$35.01 +1.13%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$14.61 $35.84

52-week range

Market cap
$818.1M
EPS (diluted)
$-3.13
Shares outstanding
23.4M
Open
Day range
Prev close
Volume
IPO date
Sep 11, 2025

LB Pharmaceuticals Inc (LBRX) Stock Price

  • Reported a net loss of $25.2M.
  • Trading near its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review LB PHARMACEUTICALS INC.

Write a review
Newsroom

News about LB PHARMACEUTICALS INC

News & sentiment via Polygon.io

FAQ

LB Pharmaceuticals Inc: frequently asked questions

Is LB Pharmaceuticals Inc an American company?

LB Pharmaceuticals Inc is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is LB Pharmaceuticals Inc headquartered?

LB Pharmaceuticals Inc is headquartered in New York, New York, United States.

Is LB Pharmaceuticals Inc publicly traded?

Yes — LB Pharmaceuticals Inc is a publicly traded company. Its stock trades under the ticker symbol LBRX on the NASDAQ.

What does LB Pharmaceuticals Inc do?

LB Pharmaceuticals Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →